| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000027295 |
| Receipt No. | R000031273 |
| Official scientific title of the study | Effect of Ingestion of Perilla Extract for 8 weeks on Pollinosis Caused by Japanese White Birch(Betula platyphylla var. japonica).: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group. |
| Date of disclosure of the study information | 2017/05/11 |
| Last modified on | 2018/07/20 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Effect of Ingestion of Perilla Extract for 8 weeks on Pollinosis Caused by Japanese White Birch(Betula platyphylla var. japonica).: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group. | |
| Title of the study (Brief title) | Effect of Ingestion of Perilla Extract for 8 weeks on Pollinosis Caused by Japanese White Birch. | |
| Region |
|
|
| Condition | |||
| Condition | Healthy adults | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To prove clinical benefits associated with 8 week ingestion of perilla extract on pollinosis caused by japanese white birch. Additionally to examine improvement of defecation status in order to evaluate the comprehensive effects of perilla extract. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | VAS questionnaire assessed pollinosis, questionnaire assessed pollinosis, white birch pollen-specific IgE |
| Key secondary outcomes | non-specific IgE, Eosinophil, TARC, questionnaire assessed defecation status, VAS questionnaire assessed defecation status, PSQ questionnaire |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | YES |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingestion of capsules containing perilla extract daily for 8 weeks. | |
| Interventions/Control_2 | Ingestion of placebo capsules daily for 8 weeks. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Subjects who have seasonal allergic symptoms (runny nose, sneezing, nose clogging, itching of the nose, itching of the eyes, watery eyes etc.) from April to June.
2.Subjects who agree to participate in this study with a written informed consent. |
|||
| Key exclusion criteria | 1.Subjects who received a diagnosis from a doctor for an allergic disease in the past year.
2.Subjects who are very heavy hay fever symptoms with pollinosis questionnaire. 3. Subjects such as acute rhinitis, sinusitis. 4.Subject who have a history of cancer of the digestive system or those who are currently treated for medication. 5.Subject who have digestive disorders. 6.Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities. 7.Subjects with major surgical history relevant to the digestive system. 8.Subjects with unusually high, low blood pressure, abnormal hematological data, severe anemia. 9.Pre- or post-menopausal women complaining of obvious physical changes. 10.Subjects who are at risk of having allergic reactions to drugs or perilla frutescens or gelatin. 11.Subject who use medicines prescribed for medical institutions for treatment of birch pollen allergy. 12.Subject who regularly take over-the-counter medicine to alleviate seasonal allergy-like symptoms. 13.Subject who regularly take prescription drugs and over-the-counter medicine for the purpose of improving bowel movements. 14.Subjects who regularly take medicine, functional foods, and/or supplements which would affect glucose metabolism. 15.Subject who can not stop taking intake of health foods and supplements or shiso juice during the examination period. 16.Excess smokers and regulars alcohol addicts or subjects with eating disordered lifestyle. 17.Subjects who donated a predetermined amount of blood in a given period. 18.Pregnant or lactating women or women who expect to be pregnant during this study. 19.Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the current study. 20.Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator. |
|||
| Target sample size | 32 | |||
| Research contact person | |
| Name of lead principal investigator | Prof. Jun NISHIHIRA, M.D., Ph.D. |
| Organization | Hokkaido Information University |
| Division name | Department of Medical Management and Informatics |
| Address | 59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan |
| TEL | 011-385-4411 |
| nishihira@do-johodai.ac.jp | |
| Public contact | |
| Name of contact person | Dir. Prof. Jun NISHIHIRA, M.D., Ph.D. |
| Organization | Hokkaido Information University |
| Division name | Health Information Science Center |
| Address | 59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan |
| TEL | 011-385-4430 |
| Homepage URL | |
| nishihira@do-johodai.ac.jp | |
| Sponsor | |
| Institute | Hokkaido Information University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Amino Up Chemical Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 北海道情報大学 保健センター(北海道) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031273 |